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Summary
Introduction: Immunotherapy by inducing oral tolerance to atherogenic self- antigens 
is gaining importance as an alternative treatment modality for atherosclerosis. The 
use of live bacterial vectors to express the recombinant antigen in vivo will obvi-
ate the need for large- scale purification of recombinant protein and may also 
augment the efficacy of oral tolerance induction.
Aim: The objective of the study was to explore the use of recombinant Mycobacterium 
smegmatis as a live vector for oral delivery of antigens to induce immune tolerance.
Method and Results: We developed a M. smegmatis vector to secrete a recombinant 
tripeptide construct (AHC; peptides from Apolipoprotein B, Heat- shock protein 60 
and Chlamydia pneumoniae outer membrane protein) expressed in a dendroaspin 
protein scaffold in pJH154 background. Immune response and oral tolerance to the 
cloned peptides were studied in C57/BL6 mice. The efficacy of this live vaccine 
to control atherosclerosis was studied in ApoE−/− knockout mice in C57/BL6 back-
ground. Oral administration of M. smegmatis secreting the cloned AHC antigen was 
found to induce tolerance to cloned protein and reduce the development of ath-
erosclerosis by 24.0% compared to control. Protection against atherosclerosis was 
associated with increase in expression of regulatory T cell- associated markers includ-
ing CTLA4 (1.8- fold), Foxp3 (2.6- fold), TGF- β (2.8- fold), IL10 (2.9- fold), and reduction 
in lipids, macrophage infiltration, and expression of inflammatory mediators in aorta.
Conclusions: Our results suggest that M.  smegmatis can be developed as an oral 
carrier of recombinant proteins to treat inflammatory autoimmune diseases.
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1 | INTRODUCTION
Atherosclerosis is a chronic inflammatory disease character-
ized by autoimmune reactivity to endogenous antigens such as 
heat- shock proteins, modified lipoproteins, and exogenous microbial 
antigens.1 Despite advances in medicine and interventional therapies, 
 cardiovascular disease remains the important cause of global death 
and disability, emphasizing the need for novel therapies targeting the 
disease pathology.2
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Antigen- based therapy targeting relevant T cells without affecting the 
general immune system provides an effective treatment for autoimmune 
diseases.3 Immunotherapy for atherosclerosis is directed toward inducing 
tolerance to atherogenic antigens by increasing the number of antigen- 
specific regulatory T cells (Tregs), which can suppress the proatherogenic 
immune response.3,4 Translation of the therapeutic effects of restoring tol-
erance to self- antigens for autoimmune and allergic diseases from animal 
models to clinical trials has been highly inconsistent.5,6 These failures are 
associated with the dose, purity, the amount of (auto) antigen needed, and 
the mode of presentation of the antigen to the mucosal immune system.7
Strategies using live bacterial cells as vaccine carriers are emerging 
as an exciting alternative for vaccine delivery. Live vaccines obviate the 
need for large- scale purification of recombinant protein, and can act 
as natural adjuvants.8,9 Several bacterial species including salmonella, 
streptococci, lactococci,10 vibrio11,12 Mycobacterium bovis (BCG),13,14 
and Mycobacterium  smegmatis15 have been used to deliver heterol-
ogous proteins. Mycobacterium  smegmatis is a nonpathogenic fast- 
growing commensal organism in humans.16 The bacterium is rapidly 
cleared by the host as it is unable to arrest phagolysosome maturation 
and evade intracellular killing.17 Mycobacterium smegmatis can be rap-
idly grown in vitro, and is amenable for genetic modification. The bac-
teria can express large amount of heterologous proteins, can activate 
dendritic cells, and generate long- lasting memory T cells, which render 
this organism an efficient vaccine carrier.18–21 Live oral vaccines based 
on lactococci have been used to restore tolerance in autoimmune dia-
betes, experimental autoimmune encephalomyelitis, and allergic dis-
eases.22,23 Mycobacterium smegmatis has not been explored so far for 
its use as a live vaccine carrier for autoimmune diseases.
Several studies have demonstrated effective early reduction of 
atherosclerosis in mouse models by inducing tolerance to peptides 
derived from Apolipoprotein B (ApoB) 100, HSPs 60/65.24–29 Immune 
tolerance is a default response in the gut as it is exposed to innumer-
able antigens through food. Antigen- presenting cells (APC) in the gut 
selectively induce antigen- specific Treg, which migrate and suppress 
damaging immune responses. We have earlier shown that oral toler-
ance to a combination of ApoB and HSP60 peptides30 and to mul-
tiantigenic recombinant molecule expressing a tripeptide derived from 
ApoB, HSP60, and outer membrane protein from Chlamydia pneumo-
niae (AHC) in a patented dendroaspin (DSP) scaffold could prevent 
atherosclerosis development in animal model of atherosclerosis.30,31 
In this study, we expressed a multiantigenic construct containing three 
atherogenic peptides in an M.  smegmatis secretory vector (pJH154) 
and explored the use of this recombinant organism in protection 
against atherosclerosis in ApoE−/− mice in C57/BL6 background.
2  | METHODS
2.1 | Generation of recombinant M. smegmatis 
expressing multiantigenic construct
The recombinant construct AHC was generated as described earlier 
and was used as a template for constructing the M.  smegmatis 
vector.32 The recombinant construct AHC was generated by insert-
ing peptides from ApoB100, hHSP60, and the combined peptide 
from major outer membrane protein and omp5 of the C. pneumoniae 
(Cpn) in the DSP scaffold as described earlier. The DNA fragments 
containing DSP backbone and the modified DSP expressing the 
three peptides (AHC) were amplified using PCR and subcloned 
into modified pET- 11d plasmid which were used as templates for 
cloning into pJH154 mycobacterial plasmid (Kind gift from Dr 
Miczak, Department of Medical Microbiology and Immunobiology, 
University of Szeged, Szeged, Hungary). Details of cloning are given 
in supplementary methods section.
2.2 | Bacterial strains and culture conditions
Plasmid containing Escherichia coli cultures were grown at 37°C in 
Luria broth, and M.  smegmatis mc2 155 was grown in Middlebrook 
7H9 medium supplemented with an albumin–dextrose–catalase (ADC; 
Hi Media Laboratories, Mumbai, India) and 0.05% Tween 80 at 
37°C. Plasmids were electroporated into competent mycobacterial 
cells as previously described.6 Transformants were selected on 
Middlebrook 7H10 medium plates containing Oleic acid ADC sup-
plement (OADC; Hi Media Laboratories) and 20 μg/mL of Kanamycin. 
Modified Sautons minimal media was used to check the expression 
of secreted protein (5.0 g l- asparagine, 1.5 g citric acid, 5.9 g 
KH2PO4, 0.6 g MgCO3, 0.5 g K2SO4, 40 mmol/L Glucose, and 
0.02% Tween 20 pH 8.0). Stock cultures of log- phase cells were 
maintained in glycerol (25% final concentration of glycerol) at −80°C.
2.3 | Colony PCR and Western blot
Single colonies of Kanamycin- resistant M. smegmatis were suspended 
in 200 μL of water, vortexed vigorously, and heated at 95°C for 
5 minutes to lyse the cells for colony PCR using the primers U1 
(5′ GGGTTA ACC ATGTTT GAC AGC TTA TCA TCGATA 3′) and 
U2 (5′ TTA GGGCCC ATGGGC AGC AG 3′). PCR- positive recom-
binant M.  smegmatis containing AHC and DSP genes were grown 
in Sautons minimal media for 3 days. Cell- free supernatants were 
concentrated and loaded on 10% SDS–PAGE gel, and the separated 
proteins were transferred onto polyvinylidene fluoride (PVDF) mem-
brane (Amersham Hibond- P Hibond-P, GE Healthcare Life sciences, 
Little Chalfont, UK) at 23 V for 45 minutes. The bound proteins 
were subsequently probed with primary antibody (mouse serum 
with known reactivity to AHC protein) at 4°C and visualized with 
HRP- conjugated anti- mouse IgG (1:2000) antibody (GE Healthcare).
2.4 | Animals
Experiments related to use of animals were carried out in accord-
ance with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the Committee for the Purpose of 
Control and Supervision of Experiments on Animals (CPCSEA), 
Ministry of Environment, and Government of India. All the protocols 
were approved by Institutional Animal Ethics Committee (Registration 
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Number: 1261/c/09/CPCSEA) and Institutional Bio Safety 
Committee (BT/BS/17/467/2012PID) of the Thrombosis Research 
Institute. C57BL/6 wild- type mice were used for immunization 
experiments, and ApoE−/− knockout mice in C57BL/6 background 
were used for the assessment of atherosclerosis.
2.5 | Immunization of mice with recombinant 
M. smegmatis
Group of four C57BL/6 mice (two males and two females) were 
immunized intraperitoneally with 108 CFU of recombinant M. smeg-
matis secreting AHC protein and control M.  smegmatis mc2 155 
in 100 μL of PBS for the evaluation of immune response to 
recombinant antigens. Two booster doses were given at an interval 
of 2 weeks each, and blood was collected after every 15 days 
to check antibody response. Spleen and the lymph nodes were 
collected 3 days after the last dose to study cell- mediated response.
2.6 | Analysis of the antibody response
Antibodies in sera from immunized mice were tested by antigen- 
specific ELISA. Briefly, 96- well microwell plates (Nalge Nunc 
International, Penfield, NY, USA) were coated with purified AHC 
protein (10 μg/mL) and incubated at 4°C overnight. Blocking was 
carried out with 5% lipid- free milk at room temperature for 1 hour, 
followed by the addition of diluted sera from mice. The bound 
immunoglobulin was assessed using horseradish peroxidase- conjugated 
goat anti- mouse IgG secondary antibody and tetramethylbenzidine 
substrate. Maleimide- activated 96- well plates (Pierce, Thermo Fisher 
Scientific Inc., Hampshire, UK) were used for coating the three pep-
tides individually, and peptide- specific antibodes were detected in 
the plasma of immunized mice according to the manufacturer’s 
instructions. The specificity of the antibodies from immunized mice 
was also confirmed by Western blot as described in the earlier 
section using immunized sera with appropriate controls.
2.7 | Analysis of T- cell response
Antigen- specific T- cell proliferation was evaluated by stimulating 
splenocytes (5×105/well) from the immunized mice with the puri-
fied AHC protein or concavalin A (10 μg/mL) for 72 hours, using 
Roche cell proliferation BrdU assay kit. Proliferating cells were 
labeled with 10 μL BrdU reagent for the last 18 hours of culture, 
fixed, and detected by anti- BrdU- POD antibody followed by sub-
strate reaction using tetramethyl benzidine, and absorbance was 
recorded by ELISA reader.
2.8 | Survival of M. smegmatis in mice after oral 
dosing
C57BL/6J wild- type mice were dosed orally with 100 μL of the 
suspension (1×108 CFU/animal). The animals were sacrificed after 
1, 24, 48, 72, 96, and 144 hours of dosing. Spleen, liver, kidney, 
lymph node, stomach, and intestine were collected, homogenized 
using sterile PBS, and colonies were enumerated on Middlebrook 
agar plates (supplemented with OADC and Kanamycin). The plates 
were checked for growth of M.  smegmatis after 3 days.
2.9 | Effect of dosage on M. smegmatis tissue burden
The effect of dosage was studied by giving 1, 3, 5, and 7 doses 
of recombinant M.  smegmatis to ApoE−/− animals by oral route 
(1×108 CFU/animal). Stomach and intestine were collected and 
homogenized using sterile PBS. Colonies were enumerated as 
described in the earlier section.
2.10 | Flow cytometry
Flow cytometry analyses were performed by FACS Canto II using 
FACS DIVA software (Becton Dickinson, Fraklin Lakes, NJ, USA) 
and FLOWJO software (Tree star, Ashland, OR, USA) as described 
earlier using anti- mouse antibodies to CD4, CD25, and fork- head 
box p3 (Foxp3).33
2.11 | Treg functional assay
Treg function was studied by antigen- specific suppression assay 
as described earlier.33 Briefly, effector T cells were generated by 
immunizing mice with purified AHC protein. CD4- positive cells from 
spleen were purified using T cell isolation kit (Miltenyi Biotech, 
Teterow, Germany) and labeled with 10 μmol/L 5, 
6- carboxyfluorescein diacetate succinimidyl ester (CFSE; Sigma 
Chemicals, St. Louis, MO, USA) and used as effector cells. Spleen 
cells from mice orally dosed with recombinant M. smegmatis secret-
ing AHC protein and regulatory T cells were isolated using the 
CD4+CD25+ regulatory T cell Isolation Kit (Miltenyi Biotech) and 
labeled with 6 μmol/L PKH26 (Sigma Chemicals) to discriminate 
the effector and regulatory CD4+ population. Effector T cells (1×105) 
and regulatory cells were taken in equal ratios and activated with 
10 μg/mL of antigen (purified AHC protein) in X vivo 20 serum- 
free medium (Lonza, Basel, Switerland). After 5 days of incubation, 
cells were stained with CD4- APC (eBiosciences, San Diego, CA, 
USA).34 Proliferation of CD4+ effector cells was measured by CFSE 
dilution using FACS CANTO II (Becton Dickinson) and analyzed 
using FlowJO software (Tree star). The proliferation index of T 
cells was calculated from the FlowJO software.
2.12 | Assessment of atherosclerosis
Groups of B6129P2- ApoEtm1Unc/J (ApoE−/−) animals (5–6 weeks 
of age) were orally dosed five times on alternate days with 108 CFU/
animal/dose of recombinant M.  smegmatis secreting AHC protein. 
Mycobacterium  smegmatis secreting DSP protein, bacteria trans-
formed with empty plasmid, and M.  smegmatis mc2 155 were used 
as controls. For comparison, purified AHC protein (1ug/dose/animal) 
was administered by oral route in separate set of ApoE−/− animals. 
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Atherosclerosis was induced using diet high in fat and cholesterol 
(TD 96121; Harlan, Indianapolis, IN, USA: 21% fat and 1.25% 
cholesterol), for 10 weeks. Quantification of atherosclerotic lesions 
was carried out as per the protocol approved by the Animal Models 
of Diabetic Complications Consortium (http://www.diacomp.org). 
Mice were euthanized humanely using an overdose of isoflurane 
inhalant anesthetic, and the hearts were collected in either optimal 
cutting temperature medium (Tissue Tek, Leica, Wetzlar, Germany) 
or neutral- buffered formalin. For lesion analysis, six sections 80 μm 
apart were stained with Elastica van Gieson in each mouse. 
Immunofluorescence on frozen sections was carried out using an 
indirect immunofluorescence technique as described earlier.30,33 
Images were captured using a Leica DMI 4000 B Confocal micro-
scope and the analysis was performed using Image- Pro software, 
and percentage areas of fluorescence of specific antigens of interest 
in the plaque were calculated.
2.13 | Real- time reverse transcription–polymerase 
chain reaction analysis
Total RNA was extracted from the ascending part of the aorta 
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Real- time reverse 
transcription–polymerase chain reaction (RT- PCR) was performed 
with two- step EXPRESS SYBR superscript RT- PCR kit (Invitrogen) 
F IGURE  1 Expression of AHC protein in Mycobacterium smegmatis. Cloning and expression of AHC and DSP protein in M. smegmatis. (A) 
The recombinant construct AHC was generated by inserting peptides from ApoB100, hHSP60, and the outer membrane proteins of Chlamydia 
pneumoniae (Cpn) in the DSP scaffold as described earlier. The fragments containing DSP (backbone and the modified DSP expressing the three 
peptides (AHC) were amplified using PCR and subcloned into modified pET- 11d plasmid which were used as templates for amplification of AHC 
and DSP genes; (B) plasmid map of pET- 11a vector and position of the U1 and U2 primers used for amplification of genes for cloning; (C) the 
amplified fragments were digested with ApaI/HpaI and ligated into pJH154 mycobacterial plasmid to obtain pJH- AHC and pJH- DSP; (D) colony 
PCR to confirm the presence of insert; Lane 1, Marker; Lane 2, M. smegmatis mc2 155 as a negative control, Lane 3, pJH- AHC- transformed 
M. smegmatis; Lane 4, pJH- DSP- transformed M. smegmatis; Lane 5 and 6, pJH- AHC- transformed Escherichia coli as a positive control; Lane 
7, pJH- DSP as a positive control; Lane 8, M. smegmatis transformed with empty pJH154 plasmid as a negative control. (E, F) Expression and 
immunoblot analysis of the concentrated culture supernatant of pJH- AHC- transformed M. smegmatis expressing AHC protein. (E) SDS–
PAGE analysis of M. smegmatis culture supernatant. Lane 1, protein molecule weight markers; lane 2, purified AHC protein; lane 3, control 
M. smegmatis mc2 155 culture supernatant; lane 4, M. smegmatis transformed with empty pJH154 plasmid; Lane 5 and 6, the supernatant of 
pJH- AHC- transformed M. smegmatis expressing target protein; and Lane 7, supernatant of pJH- DSP- transformed M. smegmatis supernatant. 
The expressed AHC protein with molecular weight about 11 kDa was pointed by an arrow. (F) Western blot analysis of the separated proteins 
as in SDS–PAGE. Lane 1, supernatant of pJH- DSP- transformed M. smegmatis supernatant; Lane 2 and 3 supernatant of pJH- AHC- transformed 
M. smegmatis expressing target protein; Lane 4, control M. smegmatis mc2 155 culture supernatant; Lane 5, M. smegmatis transformed with 
empty pJH154 plasmid; Lane 6, purified AHC protein. Data are a representative of three independent experiments. DSP, dendroaspin; AHC, 
dendroaspin expressing three peptides from ApoB, HSP60, and Cpn outer membrane protein
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using the ABI PRISM 7500 sequence detection system (7500 real- 
time PCR system; Applied Biosystems, Foster city, CA, USA) according 
to the manufacturer’s protocol using the standard cycling program. 
The sequence of primers is given in the supplementary section.
2.14 | Statistical analysis
Data are expressed as mean±standard error of mean. Differences 
between control and experimental groups were evaluated by Mann- 
Whitney U test and were considered statistically significant at P<.05. 
Statistical analyses were performed using Graph Pad prism software 
version 5.01 (GraphPad Prism Software, Inc., La Jolla, CA, USA).
3  | RESULTS
3.1 | Expression of AHC protein in M. smegmatis
Dendroaspin protein and the modified DSP scaffold containing the 
three atherogenic peptides (AHC) were cloned in pET- 15A. The 
pET constructs were used as templates for amplification of the 
genes using the U1 and U2 primers. The amplicons were digested 
with ApaI/HpaI and ligated into pJH154 mycobacterial plasmid 
which secretes the cloned proteins (Figure 1A–C). PCR was used 
to confirm the presence of cloned insert in the transformed 
M.  smegmatis colonies as shown in Figure 1D. Presence of recom-
binant construct was observed in M.  smegmatis transformed with 
pJH- AHC and pJH- DSP as an amplified DNA of ~516 and ~384 bp, 
respectively (lane 3 and 4), but not in wild- type M.  smegmatis and 
that transformed with empty plasmid (lane 2 and 8). Escherichia 
coli DH5α transformed with pJH- AHC and pJH- DSP were used 
as positive controls (lanes 5–7). The expression of the cloned 
proteins AHC and DSP was detected by SDS–PAGE and Western 
blot as shown in Figure 1E, F. Expression of protein with a molecular 
mass of ~11 KDa was detected in recombinant M.  smegmatis 
transformed with AHC and DSP genes (lanes 5 and 6), which 
matched with the purified AHC protein (lane 2). Mycobacterium 
smegmatis transformed with empty plasmid and untransformed 
M.  smegmatis mc2 155 did not show any protein reacting with 
anti- AHC antibody (lanes 3 and 4).
F IGURE  2  Immune response to AHC protein secreted from recombinant Mycobacterium smegmatis. Groups of C57BL/6 mice were given 
108 CFU of M. smegmatis expressing AHC protein, DSP protein or empty plasmid (control) followed by 2 booster doses at 14 days interval 
by intraperitoneal route. (A) AHC protein and ApoB, HSP60, and Cpn peptide- specific IgG antibodies in serum were detected by ELISA after 
second booster dose of immunization. The mean absorbance at 1:100 dilution of sera is represented in the graph and significant differences 
in ODs produced by sera of pJH- AHC- immunized mice compared to that of pJH- DSP- immunized mice are shown. (B) Immunoblot: purified 
AHC protein was separated in 10% SDS–PAGE and transferred to PVDF membrane. Immunoblot was developed with serum from immunized 
mice (lane 1, pJH- AHC; lane 2, pJH- DSP) and lane 3, control. (C) Lymphocyte proliferation assay: splenocytes were collected 3 days after the 
last immunization and at the end of the study; 1×105 cells were stimulated with either AHC protein (10 μg/mL) or concanavalin (con) A (10 μg/
mL) in vitro for 72 hours. Cell proliferation was measured by BrdU assay as quantified by measurement of fluorescence at 560 nm/590 nm. 
Splenocytes from each animal were plated in triplicates (N = 4 animals/group). Values represent mean±SEM. *P≤.05, **P≤.01, ***P≤.001
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3.2 | Immune response to AHC protein secreted 
from recombinant M. smegmatis
Good immunogens are generally good tolerogens. To understand 
the immunogenicity of secreted recombinant proteins from recom-
binant M.  smegmatis, we studied the antibody and cell- mediated 
immune response to AHC protein following intraperitoneal immu-
nization with recombinant bacteria. Mice were found to respond 
to the cloned antigen by generating a strong IgG response to 
AHC protein and the individual peptides, suggesting that the secreted 
proteins are capable of generating an immune response (Figure 2A). 
Western blot with the immunized sera showed reactivity to puri-
fied AHC protein further confirming the antigen- specific immune 
response to the cloned protein (Figure 2B). Splenocytes isolated 
from the immunized animals showed antigen- specific proliferation 
in response to stimulation with AHC protein (PI=1.46±0.11), but 
no proliferation was induced by the control antigen (0.53±0.06, 
P=.015), suggesting that the cloned protein was capable of eliciting 
a cell- mediated immune response (Figure 2C). Collectively, these 
results suggest that the recombinant protein secreted from M. smeg-
matis is immunogenic and induces an antigen- specific immune 
response in mice.
3.3 | Survival and dosage effect of M. smegmatis 
after oral administration
The main objective of the study was to induce oral tolerance to 
the cloned protein, which requires availability of the antigen at a 
low dose for sufficiently long period of time. As M.  smegmatis is 
rapidly cleared by the host, we wanted to understand the survival 
of the bacteria in different organs following oral administration and 
the optimum dosage that would generate a tolerogenic response. 
Bacterial load was detected in stomach and intestine as early as an 
hour after oral administration of 109 CFU/animal (Figure 3A–C). 
Mycobacterium  smegmatis  was found to spread to the liver at 24 
and 48 hours and was eliminated from all the organs by 96 hours 
postdosing (Figure 3A–C). Mycobacterium  smegmatis could not be 
detected in spleen, lymph nodes, and kidneys at any time point 
(data not shown).
Antigen dosage plays a very important role in inducing tolerance. 
To optimize the number of oral doses of recombinant M. smegmatis for 
effective induction of tolerance, we studied the effect of dose on the 
regulatory T cell activation and function. We observed that the num-
ber of colonies in stomach and intestine at 72 hours after the last dose 
increased with the number of oral doses and stabilized at five doses 
F IGURE  3 Survival of Mycobacterium smegmatis tissues and effect of M. smegmatis dosage in mice after oral dosing. Survival of M. smegmatis 
in mice: A single oral dose of M. smegmatis (108 CFU/dose/animal) was given to mice, and the survival of the bacteria was monitored in the 
organs Bacterial load in (A) stomach; (B) liver; (C) intestine obtained by plating serial dilutions of homogenized organs from mice. Effect of 
dosage: groups of mice were given increasing (1, 3, 5, and 7 doses) of M. smegmatis (108 CFU/dose/animal) on alternate days. (D) survival of 
bacteria in stomach and intestine, (E) percentage of Treg (CD4+, CD25+, Foxp3+) cells in spleen as measured by flow cytometry, (F) functional 
activity of Tregs, that is, proliferation index produced by effector T cells from intraperitoneally immunized mice in the presence of Treg cells 
isolated form orally treated mice 24 hours after the last oral dose of recombinant M. smegmatis secreting AHC protein
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on alternate days. Further increase in bacterial load was not observed 
after increasing the number of dose (Figure 3D). The proportion of 
regulatory T cells (CD4+CD25+Foxp3+) was not found to change with 
the number of oral doses of the recombinant M. smegmatis (Figure 3E). 
To understand the functional activity of the Tregs in suppressing the 
AHC- specific T- cell proliferation, we carried out the Treg functional 
assay. T cells isolated from mice immunized with purified AHC pro-
tein was used as effector T cells (Teff). Antigen- specific reduction in 
Teff cell proliferation was observed with Tregs from five doses (32%, 
P=.045) and seven doses (11%), but no reduction was observed from 
single and three doses of oral bacteria (Figure 3F). Based on these 
results, we chose administration of five doses of live bacteria for fur-
ther experiments.
3.4 | Effect of oral treatment with recombinant 
M. smegmatis on development of atherosclerosis
In animals treated with recombinant M.  smegmatis secreting AHC, 
30.85% of aortic sinus was covered with lesion compared to 40.62% 
in controls treated with M.  smegmatis harboring pJH 152 resulting 
in 24% (P=.003) reduction in the disease development. Interestingly, 
oral treatment with M.  smegmatis secreting DSP also resulted in 
reduction in atherosclerosis by 16% compared to control, but the 
difference was not significant (Figure 4A). In comparison, oral tol-
erance induced by purified AHC protein in ApoE−/− mice was 
observed to be 31% (P=.001) and 6% for purified DSP protein 
compared to PBS control (Figure 4B).
3.5 | Oral treatment with recombinant M. smegmatis 
reduces inflammatory mediators in aorta
To understand the mechanism of protection mediated by oral treat-
ment with M.  smegmatis secreting AHC protein, we studied the 
expression of inflammatory and regulatory molecules in the aorta 
by immunohistochemistry and real- time PCR. Deposition of lipids 
was reduced by 29.5% (P=.004) in the aorta of animals treated 
with M.  smegmatis secreting AHC protein compared to plasmid 
control (Figure 5A). AHC- treated animals showed a decrease in 
macrophage infiltration and MMP9 expression while the collagen 
content was found to be higher (Figure 5B–D). The aortic expres-
sion of inflammatory cytokines including IFN- γ (1.7- fold) and IL17 
(2.3- fold) were reduced while that of regulatory T cell activity 
including CTLA4(1.8- fold), Foxp3 (2.6- fold), TGF- β (2.8- fold), and 
IL10 (2.9- fold) were higher in AHC- treated animals (Figure 5E).
F I G U R E  4 Effect of oral dosing with recombinant Mycobacterium smegmatis on development of atherosclerosis. Groups of ApoE−/− mice 
were orally dosed five times on alternate days with 108 CFU/animal/dose of recombinant M. smegmatis secreting AHC protein. Mycobacterium 
smegmatis secreting DSP protein, bacteria transformed with empty plasmid, and purified AHC and DSP proteins (1 μg/dose/animal) in 
phosphate- buffer saline (PBS). Animals were given a diet rich in cholesterol to induce atherosclerosis for 10 weeks. Aorta were collected and 
plaque area were enumerated by histochemical analysis. Representative photomicrographs of EVG- stained plaque area and its quantitative 
analysis in aortic sinus sections of 18- week- old ApoE−/− mice (N=6 per group). (A) Groups of ApoE−/− mice were given five oral doses of 
recombinant M. smegmatis secreting AHC protein (108 CFU/animal/dose), (B) purified AHC protein (1 μg/animal/dose). Animals were given a diet 
rich in cholesterol to induce atherosclerosis for 10 weeks. Scale bar represents 200 μm
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4  | DISCUSSION
The present study provides evidence that recombinant M. smegmatis 
secreting a multiantigenic protein is immunogenic, induces a regula-
tory immune response on oral administration, and reduces the 
development of atherosclerosis in mice model, which was compa-
rable to that of purified AHC protein. The strategy to use live 
recombinant vectors secreting heterologous proteins is emerging 
as a promising alternative to the use of purified antigens as vac-
cines.8 Several species of Lactobacilli have been investigated as 
antigen delivery vehicles for inducing immune response to infec-
tious diseases as well as inducing tolerance to human proinsu-
lin.22,35,36 In this study, for the first time, we have used M. smegmatis 
to induce tolerance to self- peptides and to control atherosclerosis 
development.
Mycobacterium  smegmatis is a rapidly growing saprophyte which 
has been engineered to express antigens from viruses and bacteria 
and shown to protect against infection by efficiently cross- presenting 
the recombinant antigens.20,37–41 This strain was also found to be 
nontoxic in immunodeficient animal models lacking NK or T cells, thus 
making this vehicle a safe and suitable vaccine vector.42
Repeated administration of a low dose of antigen is known to induce 
regulatory immune response involving transforming growth factor beta 
(TGF- β) and IL- 10- producing CD4+CD25+ T regulatory cells.6,43,44 Due 
to the ease of administration and low toxicity, oral tolerance is gain-
ing importance as a therapeutic method to control unwanted immune 
F IGURE  5 Oral treatment with recombinant Mycobacterium smegmatis reduces the level of inflammatory mediators in aorta. Groups 
of ApoE−/− mice were given five oral doses of recombinant M. smegmatis secreting AHC protein 108 CFU/animal/dose as treatment and 
M. smegmatis harboring pJH 152 plasmid as control. Animals were given a diet rich in cholesterol to induce atherosclerosis for 10 weeks. (A) 
Representative photomicrographs of aortic sinus plaque area stained with Oil red O (ORO) in control (pJH154), and pJH- AHC- treated mice, 
respectively, and its quantification. Scale bar represents 200 μm (N=6). (B) Representative photomicrographs and quantitative evaluation of 
aortic sinus plaque area stained with anti- CD68 antibody for macrophages in control and treated animals. Scale bar represents 50 μm (N=6). 
(C) Representative photomicrographs and quantitative evaluation of aortic sinus plaque area stained with anti- MMP9 antibodies in control and 
treated animals. Scale bar represents 50 μm (N=6). (D) representative photomicrographs and quantitative evaluation of aortic sinus plaque area 
stained with picrosirius for collagen content in control and treated animals. Scale bar represents 50 μm (N=6). (E) Relative mRNA concentration 
of Foxp3 (2.6- fold), CTLA4 (1.8- fold), TGF- β (2.8- fold), IL10 (2.9- fold), IFN- γ (−1.7- fold), and IL17 (−2.3- fold) in the ascending aorta quantified 
by RT- PCR and normalized to GAPDH. Fold changes in mRNA expression in treated mice are calculated relative to control (n=4 mice per group). 
*P≤.05
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response.45 Although oral tolerance has demonstrated protection 
against several autoimmune and allergic diseases, clinical translation 
of results from animal models has failed mainly due to problems with 
dose, purity, and delivery of antigen to mucosal immune system.7,46 
Transgenic plants, synthetic nanoparticles, and live bacterial carriers 
are being explored for effective delivery of oral antigen to the gut.47–49
Immune tolerance is an adaptive immune response and requires an 
immunogenic antigen. Good immunogens are also good tolerogens.7 
Recombinant AHC protein secreted by M. smegmatis was found to be 
immunogenic and induced specific antibody as well as cell- mediated 
immune response. These results suggest that the cloned proteins are 
recognized by the immune system of the mice and therefore are likely 
to be recognized by the immune system of the gut to induce a sup-
pressive response.
Atherosclerosis is now recognized as a chronic inflammatory dis-
ease with immune response playing a major role in its development 
and progression. Self- reactive Th1 cells are known to migrate to 
arterial intima and amplify the inflammation during the progression 
of the disease. Oral delivery of recombinant M. smegmatis secreting 
AHC protein was able to reduce the development of atherosclerosis 
by 24.1% compared to vehicle control in ApoE−/− mice. Protection was 
associated with 29.5% lower lipid deposition in the aorta as seen by 
Oil red O staining of the sinus. Treated mice showed an increase in 
the expression of regulatory T cell markers (Foxp3 and CTLA4), anti- 
inflammatory cytokines (IL10 and TGF- β), and reduced expression of 
inflammatory markers in aorta (IFN- γ and IL17).
Orally administered antigens can directly cross the epithelium and 
enter the circulation, reach the liver via portal vein, or can be taken up 
by the intestinal microfold (M) cells, dendritic cells, and enterocytes. 
Intestinal macrophages and dendritic cells play a key role in anti-
gen uptake, presentation, and inducing antigen- specific Treg, which 
migrate and suppress damaging immune responses. Thus, it is very 
essential that the orally delivered antigen is processed and presented 
to the APCs in the gut for tolerance induction. Mycobacterium smeg-
matis is readily eliminated by phagosomal proteases, and therefore, 
unlike pathogenic mycobacteria, these bacteria are processed upon 
infection and their antigens are presented very rapidly by APC50 which 
could result in effective induction of tolerance. Our results suggest 
that M. smegmatis can be developed as an oral carrier for inducing reg-
ulatory immune response to self- proteins.
In conclusion, we have shown that oral administration of a recom-
binant M. smegmatis secreting a protein scaffold carrying three athero-
genic peptides can control the development of atherosclerosis by induc-
ing a regulatory immune response and reducing aortic inflammation. 
These preliminary results warrant further validation and improvement 
through optimization of dose and expression of recombinant construct.
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